ANAVEX 2-73 is a new class of oral, disease-modifying drug being studied to potentially treat alzheimer’s disease itself, versus treating its symptoms.
The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of ANAVEX 2-73 to determine the maximally tolerated dose in humans.
Anavex executive chairman Cameron Durrant said they are excited that the first human study for ANAVEX 2-73 is underway.
"ANAVEX 2-73 has been more than a decade in the making, so this event marks a great milestone for our company," Durrant said.